ReviewObstetrics & gynecology science2026
Prognostic and predictive roles of microsatellite instability and mismatch repair deficiency in early-stage endometrial cancer: a structured narrative review.
Review in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of endometrial cancer (EC) is rising, increasingly affecting younger women desiring fertility preservation. While the International Federation of Gynecology and Obstetrics staging system guides early-stage EC treatment, its prognostic and predictive accuracies are limited, highlighting the need for more precise tools. Molecular classification, particularly mismatch repair (MMR) status and microsatellite instability (MSI), has emerged as a promising strategy for risk stratification and personalized management. This narrative review synthesizes evidence on the role of MMR and MSI as prognostic and predictive biomarkers in early-stage EC. Using a structured narrative approach, we critically examined studies investigating molecular subtypes, especially MMR deficiency (MMRd), and their association with clinicopathological features, treatment responses, and oncological outcomes. Findings indicate that molecular profiling provides key insights beyond traditional pathology. MMRd is associated with less favorable outcomes, including higher recurrence and reduced response to hormonal or fertility-sparing therapies, potentially increasing treatment failure rates. Distinct responses to adjuvant radiation have been observed in MMRd tumors. Regarding nodal involvement, MSI has been associated with increased occult lymph node metastases, while both p53-abnormal and MMRd groups show higher rates of sentinel lymph node positivity than other subtypes. Overall, the MSI/MMRd status appears to be pivotal for improving prognosis and guiding personalized treatment of early-stage EC. Integrating molecular classification into clinical practice may optimize patient selection for conservative therapies, refine lymph node staging strategies, and inform adjuvant treatment decisions. Large prospective studies are essential to validate these findings and facilitate the adoption of standardized guidelines for individualized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.